Detalles de la búsqueda
1.
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Cardiovasc Diabetol;
23(1): 49, 2024 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302936
2.
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Am Heart J;
256: 25-36, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36372245
3.
Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.
Cardiovasc Diabetol;
22(1): 73, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36978133
4.
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
Diabetes Obes Metab;
21(6): 1429-1436, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30768845
5.
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Diabetes Obes Metab;
20(12): 2821-2829, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29974618
6.
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Cardiovasc Diabetol;
16(1): 6, 2017 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28086882
7.
Safety of Degludec versus Glargine in Type 2 Diabetes.
N Engl J Med;
377(20): 1995, 2017 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29143515
8.
Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study.
Endocr Pract;
21(2): 143-57, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25297660
9.
Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
J Am Coll Cardiol;
2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38597864
10.
Understanding the patient experience of Classic Galactosemia in pediatric and adult patients: increased disease burden, challenges with daily living, and how they evolve over time.
J Patient Rep Outcomes;
7(1): 95, 2023 09 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751006
11.
Sorbitol reduction via govorestat ameliorates synaptic dysfunction and neurodegeneration in sorbitol dehydrogenase deficiency.
JCI Insight;
8(10)2023 05 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37014713
12.
Qualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living.
Orphanet J Rare Dis;
17(1): 138, 2022 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35346295
13.
A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis.
Diabetes Metab Syndr;
15(6): 102328, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752935
14.
Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes.
Diabetes Ther;
11(6): 1293-1302, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32304086
15.
Hepatocyte growth factor protects rat RINm5F cell line against free fatty acid-induced apoptosis by counteracting oxidative stress.
J Mol Endocrinol;
38(1-2): 147-58, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17242177
16.
SWEET--where are we heading with international type 1 diabetes registries?
Pediatr Diabetes;
13 Suppl 16: 1-4, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22931218
17.
Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
Diabetes Care;
40(4): 485-493, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28188240
18.
Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets.
Diabetes;
54(2): 424-33, 2005 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-15677500
19.
Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion.
Diabetes;
54(2): 472-81, 2005 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-15677505
20.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Diabetes Care;
39(9): 1579-86, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27284114